CONTENTS

1. FUNDAMENTALS OF DRUG THERAPY IN NEUROLOGY ................................................. 1

   Michael V. Johnston M.D., and
   Faye S. Silverstein, M.D.

MOLECULAR TARGETS OF DRUG ACTION IN THE NERVOUS SYSTEM .............................. 1

   Neuronal Synaptic Action of Drugs ................................................................. 3
   Neuronal Actions on Cell Membranes and Metabolism ........................................ 20
   Drug Actions on Nonneuronal Elements ......................................................... 21
   Effects on DNA, RNA, or Protein Synthesis .................................................... 21

BARRIERS TO DRUG ACTION IN THE CNS. ................................................................. 22

   Enhancing Transport Across the BBB .............................................................. 24
   Potential Strategies to Penetrate the BBB ....................................................... 25

DYNAMIC FEATURES OF DRUG ACTION ....................................................................... 26

   Drug Delivery to the Bloodstream ................................................................. 26
   Drug Distribution ......................................................................................... 29
   Drug Metabolism ......................................................................................... 31
   Drug Elimination ......................................................................................... 31
   Pharmacokinetics ......................................................................................... 32
   Therapeutic Drug Monitoring ....................................................................... 34

TOXICITY OF NEUROACTIVE DRUGS. ........................................................................ 34

   Neurologic Disorders Attributable to Drug Therapy ........................................ 35
   Systemic Disorders Attributable to Drug Therapy ............................................ 39
   Adverse Drug Interactions ............................................................................ 41
INFLUENCE OF AGE ON DRUG ACTION
Geriatric Neuropharmacology
Pediatric Neuropharmacology
Teratogenesis

2. MOVEMENT DISORDERS
John B. Penney, Jr., M.D., and Anne B. Young, M.D., Ph.D.

NEUROCHEMICAL ANATOMY OF THE BASAL GANGLIA
Basal Ganglia Structures
Striatal Afferents
Clinical Implications

PARKINSON'S DISEASE
Clinical Manifestations
Neurotransmitter and Receptor Changes
Selective Vulnerability
Rationale for Therapy

HUNTINGTON'S DISEASE
Clinical Manifestations
Neurotransmitter and Receptor Changes
Selective Vulnerability
Rationale for Therapy

DYSTONIA
Clinical Manifestations
Neurochemical Pathology
Approach to Therapy

TREMORS
Clinical Manifestations
Neurochemical Pathology
Rationale for Therapy

TICS
Clinical Manifestations
Neurochemical Pathology
Rationale for Therapy

HEMIBALLISMUS
Clinical Manifestations
Pathology
Rationale for Therapy
3. SEIZURE DISORDERS AND EPILEPSY

Robert L. Macdonald, M.D., Ph.D.

CLASSIFICATION OF SEIZURES AND THE EPILEPSIES

CLINICAL CLASSIFICATION OF ANTICONVULSANT DRUGS

MECHANISMS OF ACTION OF ANTICONVULSANT DRUGS

Effects of Anticonvulsant Drugs on
Sodium Channels
Calcium Channels
Enhancement of GABAergic Inhibition
Effects of Anticonvulsant Drugs on Excitatory Mechanisms

MECHANISTIC CLASSIFICATION OF ANTICONVULSANT DRUGS

CLINICAL USE OF ANTICONVULSANT DRUGS FOR CHRONIC THERAPY

Decision to Initiate and Discontinue Therapy
Initiating Chronic Anticonvulsant Therapy
Therapy for Pregnant Women with Epilepsy
Therapy for Partial and Generalized Tonic-Clonic Seizures
Therapy for Absence Seizures
Therapy for Myoclonic Seizures

THERAPY FOR STATUS EPILEPTICUS

Phenytoin
Benzodiazepines ........................................ 111
Phenobarbital ........................................... 111
Pentobarbital Coma .................................... 111

4. STROKE AND HYPOXIC-ISCHEMIC DISORDERS ........................................ 118

William A. Pulsinelli, M.D., Ph.D., Michael Jacewicz, M.D., and Alastair M. Buchan, M.D., M.R.C.P.

NORMAL CEREBRAL BLOOD FLOW AND METABOLISM .................................... 118

CEREBRAL ISCHEMIA: THRESHOLDS FOR INJURY ........................................... 119

MOLECULAR CHANGES DURING ISCHEMIA ....................................................... 121

Energy Metabolism ..................................... 121
Lipid Metabolism ....................................... 121
Free Radicals .......................................... 121
Neurotransmitter Chemistry .......................... 122
Ion Homeostasis ...................................... 122

HISTOLOGIC PATTERNS OF ISCHEMIC BRAIN DAMAGE ..................................... 124

THERAPIES TO ENHANCE BRAIN OXYGEN AND SUBSTRATE SUPPLY ...................... 124

Antithrombotic Therapy ............................... 124
Anticoagulants ........................................ 129
Antiplatelet Agents .................................... 134
Thrombolytic Therapy .................................. 137
Hemodilution and Viscosity Reduction .......... 139
Perfluorochemicals .................................... 140
Vasodilator Therapy .................................... 140

EXPERIMENTAL THERAPIES TO MAINTAIN CELLULAR VIABILITY ......................... 143

Calcium Channel Antagonists ....................... 143
EAA Antagonists ....................................... 144
Reduction of Hyperglycemia and Cerebral Acidosis ........................................... 145
Antioxidants and Free-Radical Scavengers ........ 146

THERAPIES FOR STROKE EDEMA ................................................................. 146

SELECTION OF ESTABLISHED PHARMACOTHERAPIES .................................... 146
Acute Neuroleptic Side Effects ........................................ 211
Tardive Dyskinesia .................................................... 212
Neuroleptic Malignant Syndrome ................................. 213
Other Uses of Neuroleptics ........................................... 214

ANTIDEPRESSANTS ....................................................... 215
Depression ............................................................... 215
Tricyclic Antidepressants ............................................. 215
MAO Inhibitors ....................................................... 217
Antidepressants and Panic Disorder ............................. 218
Lithium ................................................................. 218

BENZODIAZEPINES ..................................................... 220

8. COGNITIVE DISORDERS ............................................. 226

Michael V. Johnston, M.D.

MEMORY DISORDERS ................................................... 226

Major Syndromes with Memory Loss ............................. 227
Organization of Memory ............................................. 227
Drug-Induced Memory Loss ....................................... 228
Roles of Neurotransmitters in Memory .......................... 229
Therapy for Memory Disorders .................................... 232

DEMENTIA ................................................................. 232

Types of Dementia .................................................... 232
Synaptic Abnormalities in AD ...................................... 233
Other Neurochemical Abnormalities in AD ..................... 238
Abnormalities in Vascular Dementia and Other Dementing Disorders ............................................. 240

THERAPY FOR DEMENTIA ............................................. 241

Approach to Assessment ............................................. 241
Symptomatic Treatment of Behavior Problems ................ 242
Cholinergic Augmentation Therapy .............................. 242
Therapies Directed Toward Other Neurotransmitter Targets .................................................. 250
"Cognition-Activating" Drugs ...................................... 250
Neuroprotection: Strategies for Promoting
  Neuron Survival or Restoring Neuron Function .............. 255

COGNITIVE DISORDERS IN YOUNG PEOPLE ...................... 256

Dyslexia and Learning Disabilities .............................. 256
Attention Deficit Disorder ........................................ 257
9. PAIN

Richard Payne, M.D., and
Gavril W. Pasternak, M.D., Ph.D.

TYPES OF PAIN

Somatic Pain
Visceral Pain
Deafferentation Pain

ACUTE VERSUS CHRONIC PAIN

ANATOMY AND PHYSIOLOGY OF CENTRAL
NOCICEPTIVE SYSTEMS

Nociceptors
Dorsal Horn and Spinothalamic Tracts
Mechanisms of Facial Sensation
The Cortex and Pain

ANTINOCICEPTIVE SYSTEMS IN THE CNS.

Endogenous Opioid Systems
Opiate Actions

PHARMACOLOGIC MANAGEMENT OF PAIN

Clinical Use of NSAIDs
Clinical Use of Opioid Analgesics
Adjuvant Analgesics
Agents to Be Avoided in the Pharmacologic
Management of Pain
Placebo Response
Pain in Children
Analgesics in the Elderly

10. ACUTE DRUG INTOXICATION

Daniel H. Lowenstein, M.D., and Roger P. Simon, M.D.

ALTERATIONS IN CONSCIOUSNESS CAUSED BY
DRUGS AND TOXINS

Mechanisms of Alterations in Consciousness
Distinguishing Intoxication from Other Causes of
Coma
Specific Agents that Produce Alterations in
Consciousness

SEIZURES CAUSED BY DRUG INTOXICATION

Opioids
Ethanol
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heterocyclic Antidepressants</td>
<td>324</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>324</td>
</tr>
<tr>
<td>Hallucinogens and Stimulants</td>
<td>325</td>
</tr>
<tr>
<td>APPENDIX: SOURCES OF DRUG INFORMATION</td>
<td>335</td>
</tr>
<tr>
<td>INDEX</td>
<td>337</td>
</tr>
</tbody>
</table>